Erin Pennock Foff Sells 15,652 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider Erin Pennock Foff sold 15,652 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $27.96, for a total value of $437,629.92. Following the completion of the sale, the insider owned 385,125 shares of the company’s stock, valued at $10,768,095. This represents a 3.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Erin Pennock Foff also recently made the following trade(s):

• On Wednesday, May 6th, Erin Pennock Foff sold 24,052 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.76, for a total transaction of $691,735.52.
• On Tuesday, May 5th, Erin Pennock Foff sold 10,576 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.20, for a total value of $298,243.20.

Maplight Therapeutics Trading Up 4.0%

Shares of NASDAQ MPLT traded up $1.12 during midday trading on Wednesday, reaching $29.04. 267,979 shares of the company traded hands, compared to its average volume of 342,018. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $33.28. The business’s 50-day moving average price is $22.60. The firm has a market capitalization of $1.24 billion and a price-to-earnings ratio of -0.73.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). Equities analysts expect that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MPLT has been the subject of a number of recent research reports. TD Cowen assumed coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They set a “buy” rating for the company. Needham & Company LLC began coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price for the company. Canaccord Genuity Group began coverage on Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target on the stock. Weiss Ratings began coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. Finally, HC Wainwright began coverage on Maplight Therapeutics in a research note on Monday. They issued a “buy” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.43.

Key Stories Impacting Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its “Buy” rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a “Buy” rating and a $45 price target (roughly mid?50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50?day moving average) that traders use to gauge technical support/resistance. Use these pages for up?to?date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright’s detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash?burn and execution risk for a clinical?stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow?up data or guidance are weak. Recent Earnings Miss

Institutional Trading of Maplight Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Strs Ohio acquired a new stake in Maplight Therapeutics during the 4th quarter worth $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics during the 4th quarter worth about $70,000. New York State Common Retirement Fund bought a new position in Maplight Therapeutics during the 4th quarter worth about $93,000. MetLife Investment Management LLC bought a new position in Maplight Therapeutics during the 4th quarter worth about $172,000. Finally, Walleye Capital LLC bought a new position in Maplight Therapeutics during the 4th quarter worth about $205,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.